Consensus Telix Pharmaceuticals Limited

Stocks

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:11:47 2026-09-25 EDT			5-day change	1st Jan Change
15.90 ^AUD	+1.02%		-10.92%	+41.96%

09-10	ASX Biggest Losers	MT
09-02	ASX Biggest Gainers	MT

Evolution of the Average Target: Telix Pharmaceuticals Limited

Evolution of the Target Price: Telix Pharmaceuticals Limited

Changes in Analyst Recommendations: Telix Pharmaceuticals Limited

5c232dc0775b.603dmYTTOdJtFAC_WM6pz7NLPlnpxxS_XNdatEenXxU.v3q_89GnfYY1JXHnHbTtmtEIVxG6r0XyEO8Y2DaWAHneeKfwyJ4MiCRicw~ac1981f10f90f65a1f1854e3e7271d0c

Analysts' recommendations: Telix Pharmaceuticals Limited

09-15	Jarden Adjusts Telix Pharmaceuticals' Price Target to AU$21 from AU$20.70, Keeps at Buy	MT
09-15	Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says	MT
07-21	Telix Pharmaceuticals Carries Meaningful Upside on Potential Product Approvals, Jefferies Says	MT
07-17	RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target	MT
07-03	Telix Pharmaceuticals Securing FDA Nod in Line With Expectations, Says Jefferies, Shares Down 3%	MT
04-15	Telix Enters Attractive Market With Late-Stage Brain Cancer Drug Trial in US, Jefferies Says	MT
04-12	Telix Pharmaceuticals' Pipeline Validated by Regeneron Deal, Citi Says	MT
04-08	Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy	MT
04-07	Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies	MT
03-01	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
01-21	Telix Pharmaceuticals Poised for Growth With Strong Illuccix Sales, Gozellix Launch, Jefferies Says	MT
01-13	Telix Pharmaceuticals Reaffirms Guidance Amid Imminent Drug Launches in US, Says Jefferies	MT
12-11	Telix Pharmaceuticals Poised for 'Solid' Q4 Revenue Growth, Jefferies Says	MT
11-12	Alerts from law firm on Telix pharmaceuticals withdrawn	RE
11-11	Telix Reports Positive Results from TLX250-CDx Imaging Trial in Triple Negative Breast Cancer Patients, Shares Fall 3%	MT
25-10-07	Barrenjoey Markets Starts Telix Pharmaceuticals at Overweight with AU$22 Price Target	MT
25-09-24	Telix Pharmaceuticals' Gozellix Expected to See Strong Sales Growth After TPT Status Grant, Jarden Research Says	MT
25-09-23	UBS Adjusts Price Target on Telix Pharmaceuticals to $20 From $23, Maintains Buy Rating	MT
25-09-19	Telix Pharmaceuticals Shows Strong Growth Potential With Blockbuster Drug Prospect, Citi Says	MT
25-09-18	Citigroup Initiates Telix Pharmaceuticals at Buy With $22 Price Target	MT
25-08-21	Telix Pharmaceuticals' Profitability Expected to Rebound, Wedbush Says	MT
25-08-06	Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy	MT
25-07-03	HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	MT
25-06-05	Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target	MT
25-01-27	UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TELIX PHARMACEUTICALS LIMITED					+49.59%
	LONZA GROUP AG					+20.9%
	IQVIA HOLDINGS INC.					+2.8%
	REVOLUTION MEDICINES, INC.					+23.88%
	BEONE MEDICINES AG					+19.94%
	CELLTRION, INC.					+50.95%
	MEDPACE HOLDINGS, INC.					-5.99%
	EUROFINS SCIENTIFIC SE					-6.61%
	ASCENDIS PHARMA A/S					+38.36%
	TEMPUS AI, INC.					-19.36%
	Average					+17.45%
	Weighted average by Cap.					+17.42%